

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SE

01 AUG 14 PM 1:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Pfizer, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 325 7th Street, N.W. Washington Suite 1200 DC 20004			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name Justin McCarthy	Telephone 202-783-7070	E-mail (optional) justin.j.mccarthy@pfizer.com	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31354000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	13. Organizations EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,840,000.00</u> Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate reporting accounting method. See instructions for description of method. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitive method. <input type="checkbox"/> Method B. Reporting amounts under section 6033(e) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature Justin McCarthy Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code AGR (one per page)
- 16. Specific Lobbying issues
**HR 2330, Agriculture Appropriations, pharmaceutical counterfeiting
Agriculture product import ban (no bills)**

- 17. House(s) of Congress and Federal agencies contacted Check if None
**Department of Agriculture
House of Representatives**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Justin McCarty* Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

HR 2330, Agriculture Appropriations, pharmaceutical counterfeiting

HR 2500, Commerce, State, Justice Appropriations, intellectual property protection

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
McCarthy, Justin	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Justin McCarthy* Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues
HR 1862 , The Greater Access to Affordable Pharmaceuticals Act of 2001, patents
S 812, The Greater Access to Affordable Pharmaceuticals Act of 2001, patent issues

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
McCarthy, Justin	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Justin M. McCarthy* Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code CSP (one per page)
- 16. Specific Lobbying issues
 - Direct to consumer advertising (no bills)**
 - Prescription and over the counter pharmaceuticals (no bills)**

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bowler, M. Kenneth	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

S 10, Medicare Prescription Drug Coverage Act of 2001, Medicare reform

S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform and prescription drug t

S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform

HR 2563, Bipartisan Patient Protection Act, liability issues

President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)

FDA user fees issue (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services

Executive Office of the President

Food & Drug Administration


House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

S 358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform

S 10, Medicare Prescription Drug Coverage Act of 2001, Prescription drug benefit

S 357, Medicare Preservation and Improvement Act of 2001, Medicare reform

President Bush's Immediate Helping Hand Proposal (no bills) (drug benefit)

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
LaMarca, Louis A.	
Judge, Dolly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2001



Registrant Name: Pfizer, Inc.

Client Name: Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

- S. 525, Andean Trade Preference Expansion Act of 2001, intellectual property protection**
- H.J. Res. 50, Resolution of Disapproval of Jackson-Vanik Waiver for China,**
- International intellectual property protection (no bills)**
- International pharmaceutical market access (no bills)**
- WTO accession and implementation issues (no bills)**
- Trade promotion authority (no bills)**

17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Commerce**
- Department of State**
- Executive Office of the President**
- House of Representatives**
- Office of U.S. Trade Representative**
- Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Bennett, Catherine P.	
Bowler, M. Kenneth	
McCarthy, Justin	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/2001

